Tenofovir-associated fanconi syndrome in a patient with chronic hepatitis B

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 3, 2014, Pages 342-

  Samarkos, Michael ^a   Theofanis, Vassileios ^a   Eliadi, Irene ^a   Vlachogiannakos, John ^a   Polyzos, Aris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ANALOGS AND DERIVATIVES; CASE REPORT; CHEMICALLY INDUCED; FANCONI SYNDROME; FATALITY; HEPATITIS B, CHRONIC; HUMAN; MALE; RISK FACTOR; VERY ELDERLY;

ADENINE; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FANCONI SYNDROME; FATAL OUTCOME; HEPATITIS B, CHRONIC; HUMANS; MALE; ORGANOPHOSPHONATES; RISK FACTORS;

EID: 84906857900     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.1543/jgld.2014.1121     Document Type: Letter

References (7)

1. Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 2013;18:945-948.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
3. Foreman JW. Fanconi syndrome and other tubular disorders. In: Floege J, Johnson RJ, Feehally J. (eds). Comprehensive Clinical Nephrology. St Louis, Elsevier Saunders, 2010:584-595.
4. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008;22:99-103.
5. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
6. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.
7. Hall AM. Update on tenofovir toxicity in the kidney. Pediatr Nephrol 2013;28:1011-1023.